What to Expect From Bio-Techne's Next Quarterly Earnings Report
Bio-Techne Corporation (TECH), a global life sciences company with an $11.3 billion market cap, is set to announce its fiscal Q4 2026 results. Analysts expect EPS of $0.46, down 9.8% year-over-year from $0.51. The company has beaten or met bottom-line estimates in each of the past four quarters. For fiscal 2026, EPS is forecast at $1.65, a 3.5% decline from fiscal 2025, but expected to grow 6.7% to $1.76 in fiscal 2027. Shares have risen 35.3% over 52 weeks, outperforming the S&P 500 and healthcare sector ETF. However, the stock fell 16.4% on May 6 after weaker-than-expected Q3 2026 results, with revenue down 2% to $311.4 million due to softer biotech spending and delayed orders. Analysts rate the stock as 'Hold' on average, with two 'Strong Buy', 12 'Hold', and one 'Strong Sell' ratings. The stock trades above the average analyst price target of $69.31.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection